The company will continue to trade on OTC markets under the symbol “IMUC” while continuing to list on a national stock exchange.

MONTVALE, NJ, November 10, 2022 /PRNewswire/ — EOM Pharmaceutical Holdings, Inc. (“EOM”), a clinical-stage pharmaceutical company, today announced its name change from ImmunoCellular Therapeutics Ltd. to EOM Pharmaceutical Holdings, Inc. EOM’s common stock will continue to trade on the over-the-counter markets under the symbol “IMUC” as the company completes the process of changing the primary listing of its common stock to a national scholarship. No action is required from the shareholders of the company with respect to the name change.

The company name change follows the merger of EOM Pharmaceuticals, Inc. and ImmunoCellular Therapeutics Ltd. December 1, 2021, in which the shareholders of EOM Pharmaceuticals became the majority shareholders of the combined company. The merger has created a public company that will focus on promoting investigational immunomodulatory and retinal drug agents to treat a range of inflammatory, viral, retinal and other diseases.

Management and organization

The management team of EOM Pharmaceutical Holdings, Inc. includes Chief Executive Officer Irach Taraporewala, Ph.D.; EOM Founder, Chairman and COO Eli Goldberger; EOM co-founder, Scientific Director and Medical Director Shalom Z. Hirschman, MD; and Wayne I. Dansonfinancial director and secretary.

About EOM Pharmaceuticals Holdings, Inc.

EOM Pharmaceutical Holdings, Inc. is a clinical-stage company focused on the development of drugs with the potential to transform therapeutic paradigms and improve the quality of life for patients suffering from debilitating and sometimes fatal diseases, including infectious diseases such as than COVID-19; autoimmune diseases, including rheumatoid arthritis; cachexia associated with AIDS and cancer; and retinal diseases. For more information about EOM Pharmaceutical Holdings, Inc., please visit www.eompharma.com.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, the benefits of the merger, the future management and board of directors of the combined company, statements regarding the ownership in the combined company of former EOM security holders and securityholders of ImmunoCellular post-merger, and EOM’s respective businesses, future operations, the advancement of its product candidates and product pipeline, the clinical development of EOM’s product candidates, including expectations regarding the timing of initiation and results of the Company’s clinical trials, the Company’s cash resources, EOM’s ability to remain listed on the over-the-counter pink market. In some cases, you can identify these statements by forward-looking words such as “may”, “will”, “continue”, “anticipate”, “intend”, “could”, “plan”, “will”. expect” or the negative or plural of these similar words or expressions, and other similar terms. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, the ability to EOM to develop and commercialize its product candidates; EOM’s ability to obtain and maintain regulatory approval for product candidates; EOM’s ability to operate in a competitive industry and compete successfully against competitors with greater resources; EOM’s dependence on third parties; EOM’s ability to obtain and adequately protect intellectual property rights for product candidates; and the effects of COVID-19 on EOM’s clinical programs and business operations. All forward-looking statements contained in this press release speak only as of the date of this press release. EOM undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.


For EOM Pharmaceuticals Holdings, Inc:

[email protected]
: 415.652.4819

MEDIA CONTACT: Pierre Collins
[email protected]
t. 908.499.1200

SOURCEEOM Pharmaceutical Holdings, Inc.